Hepatocellular Carcinoma Clinical Trial
— LIPROCESOfficial title:
Circulating Endotoxemia After Liver Resection for Hepatocellular Carcinoma in Liver Disease - Influence of Preoperative Administration of Probiotics
NCT number | NCT02021253 |
Other study ID # | 2012/130/HP |
Secondary ID | |
Status | Completed |
Phase | N/A |
First received | |
Last updated | |
Start date | April 2013 |
Est. completion date | April 12, 2018 |
Verified date | May 2018 |
Source | University Hospital, Rouen |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Surgical resection is one of the curative treatment modalities for HCC. Limits are
postoperative septic and liver functional complications related to an increase in bacterial
translocation and systemic endotoxemia. Bacterial translocation is a passage of bacteria and
bacterial degradation products from the intestine to the portal circulation. The endotoxemia
secondary to bacterial translocation, stimulates endothelial production of nitric oxide (NO).
NO is also a potent inducer of membrane instability, responsible for an increase in the
permeability of the vascular endothelium and intestinal mucosa, possibly contributing to a
worsening of bacterial translocation.
Probiotics are live microorganisms which when administered in adequate amounts, provide a
health benefit on the host ((Health and Nutritional Properties of Probiotics in Food
Including Powder Milk with Live Lactic Acid Bacteria - Cordoba Argentina October 2001). Data
from experimental and clinical literature show a significant effect of probiotics on the
improvement of liver function and a decrease in infectious complications in patients with
chronic liver disease. The proposed study would evaluate the effect preventive and
therapeutic in a population of surgical patients, in whom the intestinal portal and hepatic
inflammation promotes postoperative complications.
Status | Completed |
Enrollment | 64 |
Est. completion date | April 12, 2018 |
Est. primary completion date | April 12, 2018 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Agreement signed by the patient - Diagnosis of HCC confirmed - Diagnosis of liver disease (score F3 or F4) confirmed - Indication of surgical resection confirmed and validated by a specialist multidisciplinary assessment meeting of gastrointestinal oncology - Patient operable (no indication against anaesthesiological) - Resectable tumor lesion (surgical expertise) - Laboratory tests and endoscopy: No suspicion of severe portal hypertension with bleeding risk Exclusion Criteria: - Patient not willing, at risk of default of compliance, or patient can not be monitored regularly - Antibiotic extended or terminated for less than 1 month, may limit the effects of taking probiotics. - Inflammatory Bowel Disease, which could skew the results expected by taking probiotics results. |
Country | Name | City | State |
---|---|---|---|
France | University Hospital | Rouen | Haute Normandie |
Lead Sponsor | Collaborator |
---|---|
University Hospital, Rouen |
France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Area under the plasma concentration versus time curve (AUC) of endotoxins circulating levels | -12, 3, 12,24, 72, 120 hours at time of surgery |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04209491 -
Interest of the Intervention of a Nurse Coordinator in Complex Care Pathway
|
||
Completed |
NCT03963206 -
Cabozantinib toLERANCE Study in HepatoCellular Carcinoma (CLERANCE)
|
Phase 4 | |
Completed |
NCT03268499 -
TACE Emulsion Versus Suspension
|
Phase 2 | |
Recruiting |
NCT05044676 -
Immune Cells as a New Biomarker of Response in Patients Treated by Immunotherapy for Advanced Hepatocellular Carcinoma
|
||
Recruiting |
NCT05263830 -
Glypican-3 as a Prognostic Factor in Patients With Hepatocellular Carcinoma Treated by Immunotherapy
|
||
Recruiting |
NCT05095519 -
Hepatocellular Carcinoma Imaging Using PSMA PET/CT
|
Phase 2 | |
Recruiting |
NCT05497531 -
Pilot Comparing ctDNA IDV vs. SPV Sample in Pts Undergoing Biopsies for Hepatobiliary and Pancreatic Cancers
|
N/A | |
Completed |
NCT05068193 -
A Clinical Trial to Compare the Pharmacokinetics and Bioequivalence of "BR2008" With "BR2008-1" in Healthy Volunteers
|
Phase 1 | |
Active, not recruiting |
NCT03781934 -
A Study to Evaluate MIV-818 in Patients With Liver Cancer Manifestations
|
Phase 1/Phase 2 | |
Terminated |
NCT03655613 -
APL-501 or Nivolumab in Combination With APL-101 in Locally Advanced or Metastatic HCC and RCC
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT03170960 -
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT04242199 -
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid Tumors
|
Phase 1 | |
Completed |
NCT04401800 -
Preliminary Antitumor Activity, Safety and Tolerability of Tislelizumab in Combination With Lenvatinib for Hepatocellular Carcinoma
|
Phase 2 | |
Withdrawn |
NCT05418387 -
A Social Support Intervention to Improve Treatment Among Hispanic Kidney and Liver Cancer Patients in Arizona
|
N/A | |
Active, not recruiting |
NCT04039607 -
A Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Hepatocellular Carcinoma
|
Phase 3 | |
Terminated |
NCT03970616 -
A Study of Tivozanib in Combination With Durvalumab in Subjects With Advanced Hepatocellular Carcinoma
|
Phase 1/Phase 2 | |
Recruiting |
NCT04118114 -
Phase II Study of PRL3-ZUMAB in Advanced Solid Tumors
|
Phase 2 | |
Recruiting |
NCT03642561 -
Evaluation the Treatment Outcome for RFA in Patients With BCLC Stage B HCC in Comparison With TACE
|
Phase 2/Phase 3 | |
Recruiting |
NCT06239155 -
A Phase I/II Study of AST-3424 in Subjects With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Completed |
NCT03222076 -
Nivolumab With or Without Ipilimumab in Treating Patients With Resectable Liver Cancer
|
Phase 2 |